

Compliance Issues in the Context of Public Health: Practical Perspectives - THE MALAYSIAN PERSPECTIVE



Unny Sankar Ravi Sankar
Policy and International Relations
Division, Ministry of Health Malaysia

11 July 2012

Overview

- 1. Laws & Regulations Relevant to IPR - Health**
- 2. IPR Provisions Related to Pharmaceutical Products**
- 3. Ministries/ Agencies Involved**
- 4. FTAs**

Laws & Regulations Relevant to IPR & Health

- **Act 291: Patents Act 1983**
- **Drug and Cosmetic Regulations 1989**
- **Directive under Regulation 29 of the Control of Drugs and Cosmetic Regulations 1984**

IPR Provisions Related to Pharmaceutical Products

- **Data Exclusivity (DE)**
- **Patent Term Restoration (PTR)**
- **Patent Linkage**
- **Parallel Imports**
- **Compulsory Licensing**

Data Exclusivity (DE)

**Drug
Regulatory
Authority**

**Clinical
Test
Data**

- **Safety**
- **Efficacy**
- **Quality**



**Generic Drug
Manufacturer**


DE (cont.)

- **Within 20 years of patent**
- **Global Exhaustion – 18 months**
- **5 years for new drug product** **new chemical entity**
- **3 years for second indication of a registered product**

DE (cont.)

- DRA holds the right to issue DE
- Dosage strength and forms - **not allowed**
- right to issue compulsory license **will not be affected**

Term Restoration (PTR)



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_7532



based on EU's PTR model